These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 36739905)

  • 1. Current Threat of Nitrosamines in Pharmaceuticals and Scientific Strategies for Risk Mitigation.
    Tuesuwan B; Vongsutilers V
    J Pharm Sci; 2023 May; 112(5):1192-1209. PubMed ID: 36739905
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regulatory Experiences with Root Causes and Risk Factors for Nitrosamine Impurities in Pharmaceuticals.
    Horne S; Vera MD; Nagavelli LR; Sayeed VA; Heckman L; Johnson D; Berger D; Yip YY; Krahn CL; Sizukusa LO; Rocha NFM; Bream RN; Ludwig J; Keire DA; Condran G
    J Pharm Sci; 2023 May; 112(5):1166-1182. PubMed ID: 36599405
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nitrosamine Contamination in Pharmaceuticals: Threat, Impact, and Control.
    Tuesuwan B; Vongsutilers V
    J Pharm Sci; 2021 Sep; 110(9):3118-3128. PubMed ID: 33989680
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nitrosamine Impurities in Herbal Formulations: A Review of Risks and Mitigation Strategies.
    Shekhar NR; Nagappan K; Singh MT; Dhanabal SP
    Drug Res (Stuttg); 2023 Oct; 73(8):431-440. PubMed ID: 37487523
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An update on the current status and prospects of nitrosation pathways and possible root causes of nitrosamine formation in various pharmaceuticals.
    Wichitnithad W; Nantaphol S; Noppakhunsomboon K; Rojsitthisak P
    Saudi Pharm J; 2023 Feb; 31(2):295-311. PubMed ID: 36942272
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nitrosamine Impurities in Angiotensin Receptor Blockers.
    Shephard EA; Nawarskas JJ
    Cardiol Rev; 2020; 28(5):262-265. PubMed ID: 32467427
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comprehensive review of sources of nitrosamine contamination of pharmaceutical substances and products.
    Akkaraju H; Tatia R; Mane SS; Khade AB; Dengale SJ
    Regul Toxicol Pharmacol; 2023 Mar; 139():105355. PubMed ID: 36792049
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Nitrite Excipient Database: A Useful Tool to Support N-Nitrosamine Risk Assessments for Drug Products.
    Boetzel R; Schlingemann J; Hickert S; Korn C; Kocks G; Luck B; Blom G; Harrison M; François M; Allain L; Wu Y; Bousraf Y
    J Pharm Sci; 2023 Jun; 112(6):1615-1624. PubMed ID: 35500671
    [TBL] [Abstract][Full Text] [Related]  

  • 9. METASTATIC NODULAR MELANOMA DEVELOPING ON NEVUS SPILUS DURING INTAKE OF BETA BLOCKERS (BISOPROLOL/NEBIVOLOL) AND ACE INHIBITORS (PERINDOPRIL). POTENTIAL LINKS TО THE DRUG RELATED NITROSOGENESIS/CARCINOGENESIS, DUNNING-KRUGER EFFECT AND GENETIC WEAPONS OF THE NEW GENERATION.
    Tchernev G
    Georgian Med News; 2023 Oct; (343):172-178. PubMed ID: 38096536
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A GC-MS/MS Method for Trace Level Quantification of Six Nitrosamine Impurities (NDMA, NDEA, NEIPA, NDIPA, NDPA, and NDBA) in Commercially Used Organic Solvents: Dichloromethane, Ethyl Acetate, Toluene, and O-xylene.
    Kosuri ER; Bhanti M; Jaywant MA; Han M; Wang X; Obeng M
    J Pharm Sci; 2023 May; 112(5):1225-1230. PubMed ID: 36462706
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In Silico Prediction of N-Nitrosamine Formation Pathways of Pharmaceutical Products.
    Tsuji G; Kurohara T; Shoda T; Yokoo H; Ito T; Masada S; Uchiyama N; Yamamoto E; Demizu Y
    Chem Pharm Bull (Tokyo); 2024; 72(2):166-172. PubMed ID: 38296559
    [TBL] [Abstract][Full Text] [Related]  

  • 12. On the Risk of Nitrosamine Contamination During Drug Product Blister Packaging.
    Zheng J; Brookes A; Moser J; Pfeffer H; Smith A
    J Pharm Sci; 2023 Sep; 112(9):2321-2325. PubMed ID: 37478970
    [TBL] [Abstract][Full Text] [Related]  

  • 13. N-Nitrosamine Formation in Pharmaceutical Solid Drug Products: Experimental Observations.
    Moser J; Ashworth IW; Harris L; Hillier MC; Nanda KK; Scrivens G
    J Pharm Sci; 2023 May; 112(5):1255-1267. PubMed ID: 36736774
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nitroso Impurities in Drug Products: An Overview of Risk Assessment, Regulatory Milieu, and Control Strategy.
    Charoo NA; Dharani S; Khan MA; Rahman Z
    AAPS PharmSciTech; 2023 Feb; 24(2):60. PubMed ID: 36759424
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MULTIPLE BCCS AND DYSPLASTIC NEVI AFTER ACE INHIBITORS (ENALAPRIL/PERINDOPRIL): THE ROLE OF NITROSAMINE CONTAMINATION/AVAILABILITY AS SUBSTANTIAL SKIN CANCER TRIGGERING FACTOR.
    Tchernev G; Kordeva S
    Georgian Med News; 2023 Feb; (335):90-94. PubMed ID: 37042596
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nitrosamine Impurities in Pharmaceuticals: An Empirical Review of their Detection, Mechanisms, and Regulatory Approaches.
    Bhirud D; Agrawal G; Shah H; Patel A; Palkar MB; Bhattacharya S; Prajapati BG
    Curr Top Med Chem; 2024; 24(6):503-522. PubMed ID: 38321910
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current status and prospects of development of analytical methods for determining nitrosamine and N-nitroso impurities in pharmaceuticals.
    Wichitnithad W; Nantaphol S; Noppakhunsomboon K; Thitikornpong W; Rojsitthisak P
    Talanta; 2023 Mar; 254():124102. PubMed ID: 36470020
    [TBL] [Abstract][Full Text] [Related]  

  • 18. METATYPICAL BCCS OF THE NOSE TREATED SUCCESSFULLY VIA BILOBED TRANSPOSITION FLAP: NITROSAMINES IN ACES (ENALAPRIL), ARBS (LOSARTAN) AS POSSIBLE SKIN CANCER KEY TRIGGERING FACTOR.
    Tchernev G; Kordeva S; Lozev I
    Georgian Med News; 2023 Feb; (335):22-25. PubMed ID: 37042583
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Performance Characteristics of Mass Spectrometry-Based Analytical Procedures for Quantitation of Nitrosamines in Pharmaceuticals: Insights from an Inter-laboratory Study.
    Yang J; Kakarla R; Marzan T; Sherwin B; George M; Bennett J; Basutto J; Su Y; Ollerenshaw J; Morin J; Rebière H; Maggio AF; Kermaïdic A; Gervela E; Brenier C; Civade C; Chauvey D; Duperray F; Wollein U; Conti M; Tromp J; Meyer S; Wanko R; Wierer M; Bertrand M; Rodriguez J; Sommers C; Keire D
    J Pharm Sci; 2023 Oct; 112(10):2685-2695. PubMed ID: 37524228
    [TBL] [Abstract][Full Text] [Related]  

  • 20. N-nitrosamine Mitigation with Nitrite Scavengers in Oral Pharmaceutical Drug Products.
    Bayne AV; Misic Z; Stemmler RT; Wittner M; Frerichs M; Bird JK; Besheer A
    J Pharm Sci; 2023 Jul; 112(7):1794-1800. PubMed ID: 37023856
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.